University of Rhode Island - College of Pharmacy’s Post

VACUNAS. Efficacy of Six Different SARS-CoV-2 Vaccines during a six-month follow-up and five COVID-19 waves in Brazil and Mexico. Dr. David. #director #gerente #farma #industriafarmacéutica #industriafarmaceutica #vacunas #vaccines #covid #pharma #bigpharma

Non-COVID-19 Vaccines Get Post-Pandemic Boost, reports Kalorama Information Increases were notable in several vaccine areas, including: - #Shingles - #HPV - #Meningitis - #Rotavirus - #RSV Read more in the latest blog by Kalorama Information - https://lnkd.in/gjErcmgu #Vaccine #Vaccines #Covid19 #marketresearch #mrx #healthcare #Pharmaceuticals #pandemic

Meningococcal Vaccines Market is projected to grow at a CAGR of 6.32% by 2033 #Vaccines #TherapeuticDrugs > Download this new #Pharma report here > https://ow.ly/boq050Qmi2t

New free mini CPD module released – a how to guide on drawing up Covid-19 vaccines! As pharmacists, it's crucial to stay updated on best practices, and this FREE session offers exactly that. Don't wait, start the CPD now #VaccineTraining #Pharmacy #CPD https://ow.ly/NCSh50RsCk3

Register now for this live webinar on new drug and vaccine approvals! Nicole Pezzino, PharmD, BCACP, CDCES, will include a list of novel medications and vaccines approved in 2023 with information about each of their indications. Learn more: https://bit.ly/3HnAkZq Learner level: Foundational #PTCE #FreeCE #LiveWebinar

The pharmaceutical giant AstraZeneca has announced the global withdrawal of its COVID-19 vaccine, Covishield, mere weeks after acknowledging rare side effects associated with the shot. The decision, outlined in a report by The Telegraph, cites commercial reasons for the removal from markets worldwide. The vaccine, developed in collaboration with the University of Oxford, was once hailed as a beacon of hope in the fight against the pandemic. Covishield, manufactured and supplied by the Serum Institute of India (SII), played a pivotal role in vaccination drives across low-and-middle-income countries. However, concerns over its safety have loomed large following reports of adverse reactions, including Thrombosis with Thrombocytopenia Syndrome (TTS), a condition causing blood clots and low blood platelet count. The application to withdraw the vaccine, submitted on March 5 and effective as of Tuesday, comes amidst mounting legal challenges. A class action lawsuit alleges that AstraZeneca's vaccine led to deaths and serious injuries, with plaintiffs claiming damages of up to £100 million. Despite the company's admission of rare side effects, it vehemently denies any link between the withdrawal and the ongoing court case. 𝒇𝒐𝒓 𝒎𝒐𝒓𝒆 𝒅𝒆𝒕𝒂𝒊𝒍𝒔👇👇👇 https://lnkd.in/gxSJEN58 #AstraZeneca #Covishield #VaccineWithdrawal #COVID19 #SafetyConcerns

Expand your reach and boost your ROI by vaccinating patients you never had access to before! Billing for just 15 Flu vaccines or 9 COVID vaccines with Provider CSAO can kickstart your returns. Access a wider proportion of your patient population and witness your investment flourish today. Ready to make a difference? Contact us today → https://bit.ly/3W5ciIy #ClinicalPharmacy #MedicationManagement #PharmaceuticalCare #PharmacyPractice #PatientSafety #DrugTherapy #Pharmacotherapy #ClinicalPharmacist #PharmacyEducation #EvidenceBasedMedicine

A raft of Pharma companies are positing quarterly updates at the moment with mixed results. 💉 BioNTech SE are now aiming for $4b sales of their Covid vaccine - $1b lower than forecast and a whopping $13b reduction from peak. 💉 Moderna posted a net $3.6b loss. Lower vaccine demand again playing a big part. 💉 AstraZeneca post on Thursday, one of the other major vaccine manufacturers. 💉 Novo Nordisk posted 30% quarterly growth as it struggles to keep up with demand for it's blockbuster weight loss product Wegovy Are pharma companies profiteering from pandemics and societal crises? Or do they play a pivotal role in R&D and keeping the public healthy? #pharma #quarterlyresults #researchanddevelopment #supplychain #logistics https://lnkd.in/gn2cpevC

UK-based pharmaceutical giant AstraZeneca is withdrawing its COVID-19 vaccine globally, days after acknowledging in court documents that it can cause a rare and dangerous side effect. The company had earlier accepted a connection between the vaccine and Thrombosis with Thrombocytopenia Syndrome (TTS), a condition marked by unusually low levels of platelets combined with blood clot formation. However, calling the decision "purely coincidental," the pharma giant stated that the vaccine is being withdrawn due to a "surplus of available updated vaccines" since the pandemic. "As multiple variant COVID-19 vaccines have since been developed, there is a surplus of available updated vaccines," the company said. AstraZeneca said that the surplus had led to a decline in demand for its vaccine, known as Vaxzevria since 2021, which is no longer being manufactured or supplied. According to a Telegraph report, The vaccine can no longer be used in the European Union after the company voluntarily withdrew its “marketing authorisation”. The report said the application to withdraw the vaccine was made on March 5 and came into effect on May 07, 2024. Similar withdrawal applications will be submitted in the UK and other countries. #vaccine #pharmaceuticals #pharma #india #covid19 #company #Indianstartupnews

Breaking News: We have expanded our partnership with GPN Vaccines and will be manufacturing large-scale cGMP batches for their proprietary engineered whole-cell vaccine program, Gamma-PN™, which protects against Streptococcus pneumoniae. This bacterium is responsible for life-threatening infections that cause up to 2 million deaths worldwide each year. Our CEO Mark W. Womack declared “We are extremely proud that GPN Vaccines has asked us to further scale-up the production of Gamma-PN™, which has the potential to protect so many lives against a broad range of serotypes not covered by any current vaccines.” Learn more about our collaboration in the full press release here: https://lnkd.in/ggampJpq #biomanufacturing #BiologicsCDMO #microbial #pDNA #mRNA #Vaccine #cGMP